Dangerous Work
By Editorial,
Nature
| 10. 02. 2013
Intelligence tests were first devised in the early twentieth century as a way to identify children who needed extra help in school. It was only later that the growing eugenics movement began to promote use of the tests to weed out the less intelligent and eliminate them from society, sparking a debate over the appropriateness of the study of intelligence that carries on to this day. But it was not the research that was problematic: it was the intended use of the results.
As the News Feature on
page 26 details, this history is never far from the minds of scientists who work in the most fraught areas of behavioural genetics. Although the ability to investigate the genetic factors that underlie the heritability of traits such as intelligence, violent behaviour, race and sexual orientation is new, arguments and attitudes about the significance of these traits are not. Scientists have a responsibility to do what they can to prevent abuses of their work, including the way it is communicated. Here are some pointers.
First: be patient. Do not speculate about the...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...